📊 This is a company profile preview from Tablestat.com Request a Free Trial Now

Company profile: Promedior

1.1 - Company Overview

Promedior Logo

Promedior

Headquarter: United States
Founded: 20XX🔒
Employees: 100-500🔒

Company description

  • Provider of clinical-stage biopharmaceutical therapeutics for inflammatory and fibrotic diseases, supported by a novel drug discovery platform to regulate monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases.

Products and services

🔒

Key contacts

🔒
🔒

Financial details

🔒

1.2 - Competitors and similar companies to Promedior

Aclaris Therapeutics Logo

Aclaris Therapeutics

HQ: United States Website
  • Description: Provider of dermatologic and immuno-inflammatory therapies R&D, using its KINect platform to discover small-molecule kinase inhibitors; conducts clinical trials; offers drug discovery and early development via Confluence Discovery Technologies; advancing ATI-1777 (topical JAK1/JAK3), ATI-2138 (oral ITK/JAK3), and Zunsemetinib/ATI-450 (oral MK2) for metastatic breast cancer and pancreatic ductal adenocarcinoma.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Aclaris Therapeutics company profile →
EpiBiologics Logo

EpiBiologics

HQ: United States Website
  • Description: Provider of antibody-based targeted therapies and platforms for tissue-specific degradation of disease-driving membrane and extracellular proteins, including the EpiTAC platform (bispecific antibody system), AbTACs, KineTACs, TrainTAC degrader, and the EpiAtlas platform with a library of over 270 degrader arms.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full EpiBiologics company profile →
Exagen Logo

Exagen

HQ: United States Website
  • Description: Provider of diagnostic and monitoring tests for autoimmune rheumatic diseases, including AVISE CTD and AVISE Lupus for SLE diagnosis using CB-CAPs, AVISE SLE Monitor for disease activity, AVISE SLE Prognostic for risk of thrombosis, cardiovascular events, lupus nephritis and neuropsychiatric lupus, AVISE APS for antiphospholipid syndrome and thrombosis risk, and AVISE MTX to assess methotrexate exposure.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Exagen company profile →
Noveome Biotherapeutics Logo

Noveome Biotherapeutics

HQ: United States Website
  • Description: Provider of regenerative repair therapies for inflamed or damaged tissues via ST266, a multi-targeted secretome of biologically active proteins for neuroprotection, inflammation modulation, cell recovery, and healing in ophthalmology, neurology, and dermatology; explored in PEDs, optic neuritis, glaucoma (Phase I), NEC, and COVID-19/sepsis cytokine storm.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Noveome Biotherapeutics company profile →
Kezar Life Sciences Logo

Kezar Life Sciences

HQ: United States Website
  • Description: Provider of drug discovery and development focused on protein homeostasis, offering Zetomipzomib (KZR-616), a selective immunoproteasome inhibitor for autoimmune diseases via immune modulation without direct immunosuppression, and KZR-261, a first-in-class Sec61 translocon inhibitor for advanced/metastatic solid tumors that blocks key secreted proteins.
  • Rationale: This competitor operates in a highly similar market segment with overlapping features.
  • Company type: Private company
  • Employees: ●●●●●
  • Total funding raised: $●●●m
  • Backers: ●●●●●●●●●●
  • Acquisitions: ●●
View full Kezar Life Sciences company profile →
🔒

2.M&A buyers

2.1 Potential strategic acquirers in the sector

🔒
🔒
🔒
🔒 View all strategic buyers with complete profiles
Start Free Trial →

2.2 - Strategic buyer groups for Promedior

🔒

Buyer group 1: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 2: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔒

Buyer group 3: ████████ ████████

●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒 View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →

3. Investors and private equity firms

3.1 - Buyout funds investing in similar companies to Promedior

2.2 - Growth funds investing in similar companies to Promedior

🔒 View all growth equity funds with complete profiles
Start Free Trial →

4 - Top valuation comps for Promedior

4.2 - Public trading comparable groups for Promedior

🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →

4.3 - M&A Transactions similar to Promedior

Selected M&A transactions

Date Target Description Buyer(s) Relevance EV EV/Revenue EV/EBITDA
🔒 View all M&A transactions with complete deal terms
Request Free Trial Now →

Frequently Asked Questions

About Promedior

What does Promedior do?

Promedior is a provider of clinical-stage biopharmaceutical therapeutics for inflammatory and fibrotic diseases, supported by a novel drug discovery platform to regulate monocyte-derived cell populations that play key roles in fibrotic, inflammatory and autoimmune diseases.

Who are Promedior's competitors?

Promedior's competitors and similar companies include Aclaris Therapeutics, EpiBiologics, Exagen, Noveome Biotherapeutics, and Kezar Life Sciences.

Where is Promedior headquartered?

Promedior is headquartered in United States.

How many employees does Promedior have?

Promedior has 1,000 employees 🔒.

When was Promedior founded?

Promedior was founded in 2010 🔒.

What sector and industry vertical is Promedior in?

Promedior is in the Enterprise Software 🔒 sector and industry

M&A Buyers & Acquirers for Promedior

Who are the top strategic acquirers in Promedior's sector and industry

Top strategic M&A buyers and acquirers in Promedior's sector include ████████, ██████████, ██████, ████████, and ██████████ 🔒.

Which M&A buyer groups are most relevant for Promedior?

Top strategic M&A buyers groups and sectors for Promedior include █████████████████ , ████████████████, █████████████, ████████████, and ████████████████ 🔒.

Financial Investors investing in Promedior's sector and industry vertical

Which are the top PE firms investing in Promedior's sector and industry vertical?

Top PE firms investing in Promedior's sector and industry vertical include ████████, ██████████, ████████, and ██████████ 🔒.

Who are the top buyout funds acquiring in Promedior's sector and industry vertical?

Active PE funds and buyout funds acquiring companies in Promedior's sector and industry vertical include █████████, ██████████, ████████████, and ████████████ 🔒.

Who are the top growth equity funds investing in companies in Promedior's sector and industry vertical?

Growth funds and venture capital funds investing in companies similar to Promedior include █████████, ██████████, ████████████, and ████████████ 🔒.

Valuation benchmarks of companies in Promedior's sector and industry

Which are the key public companies that are relevant trading comps benchmarks for Promedior?

The key public trading comparables and valuation benchmarks for Promedior include █████████, ██████████, ████████████, and ████████████ 🔒.

Which are the key trading comparable groups for Promedior for public valuation benchmarks?

Our platform tracks detailed public trading comparable groups and valuation benchmarks for Promedior with complete valuation multiples, growth metrics, and profitability data. Access the full database to benchmark your company against relevant public comparables.

What are recent M&A transactions in Promedior's sector and industry vertical?

Our platform tracks relevant M&A transactions comparables and valuation benchmarks for Promedior with complete deal terms, valuation multiples, and strategic rationale. Access the full database to benchmark pricing and identify active acquirers.

What are recent capital raises and funding rounds in Promedior's' sector and industry vertical?

Access recent funding rounds and capital raises in Promedior's sector and industry vertical including growth equity, venture capital, and buyout investments. Our database includes round size, lead investors and valuations.

Ready to Find the Right Buyers?

Access complete buyer lists, valuation data, and M&A intelligence for Promedior